Neurocrine Biosciences (NBIX) Equity Income: 2019-2021
Historic Equity Income for Neurocrine Biosciences (NBIX) over the last 2 years, with Sep 2021 value amounting to -$8.2 million.
- Neurocrine Biosciences' Equity Income fell 17.14% to -$8.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$3.2 million, marking a year-over-year increase of 83.49%. This contributed to the annual value of -$13.0 million for FY2019, which is N/A change from last year.
- Latest data reveals that Neurocrine Biosciences reported Equity Income of -$8.2 million as of Q3 2021, which was down 1,271.43% from $700,000 recorded in Q1 2021.
- In the past 5 years, Neurocrine Biosciences' Equity Income ranged from a high of $21.0 million in Q2 2019 and a low of -$28.5 million during Q3 2019.
- Moreover, its 3-year median value for Equity Income was -$7.0 million (2020), whereas its average is -$3.6 million.
- Per our database at Business Quant, Neurocrine Biosciences' Equity Income slumped by 1,070.59% in 2020 and then skyrocketed by 104.24% in 2021.
- Quarterly analysis of 3 years shows Neurocrine Biosciences' Equity Income stood at -$7.2 million in 2019, then spiked by 75.44% to -$7.0 million in 2020, then decreased by 17.14% to -$8.2 million in 2021.
- Its Equity Income stands at -$8.2 million for Q3 2021, versus $700,000 for Q1 2021 and -$7.0 million for Q3 2020.